Asset profile
Dalcetrapib (RO4607381)
Unknown / undisclosed
Evidence outlook · results not reported
NCT00658515 · Coronary Heart Disease
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT00658515: This was a randomized, double-blind, placebo-controlled trial with 15,871 participants and a hard clinical primary endpoint measuring cardiovascular morbidity and mortality. However, the statistical significance of the primary comparison is not reported, and the posted event rates do not establish a clear favorable effect for dalcetrapib.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
62 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 18 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Dalcetrapib (RO4607381): this drug | Phase 3 | — | CETP | ||
| Dalcetrapib | Phase 3 | Small molecule | CETP | ||
| Obicetrapib | Phase 3 | Small molecule | CETP | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Bempedoic Acid (Nexletol) | Approved | Small molecule | Adenosine Triphosphate-Citrate Lyase Inhibitor, ATP citrate lyase | ||
| Bempedoic Acid / Ezetimibe | Approved | Small molecule | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) | ||
| Cangrelor (Kengreal) | Approved | Small molecule | P2Y12 receptor | ||
| Colchicine (cardiovascular) (Lodoco) | Approved | Small molecule | Microtubule/inflammasome (tubulin) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | ||
| Icosapent Ethyl (Vascepa) | Approved | Small molecule | Omega-3 fatty acid (EPA) | ||
| Inclisiran (Leqvio) | Approved | RNA / oligonucleotide | PCSK9 | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Lomitapide (Juxtapid) | Approved | Small molecule | MTP | ||
| Nexlizet | Approved | — | — |
…and 47 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
August 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.